<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04146038</url>
  </required_header>
  <id_info>
    <org_study_id>Pro2019001209</org_study_id>
    <secondary_id>NCI-2019-07031</secondary_id>
    <secondary_id>Pro2019001209</secondary_id>
    <secondary_id>021905</secondary_id>
    <secondary_id>P30CA072720</secondary_id>
    <nct_id>NCT04146038</nct_id>
  </id_info>
  <brief_title>Salsalate, Venetoclax, and Decitabine or Azacitidine for the Treatment of Acute Myeloid Leukemia or Advanced Myelodysplasia/Myeloproliferative Disease</brief_title>
  <official_title>Salsalate + Venetoclax/Decitabine for Patients With Acute Myelogenous Leukemia or Advanced Myelodysplasia/Myeloproliferative Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rutgers, The State University of New Jersey</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Rutgers, The State University of New Jersey</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase II trial studies the side effects of salsalate when added to venetoclax and&#xD;
      decitabine or azacitidine in treating patients with acute myeloid leukemia or&#xD;
      myelodysplasia/myeloproliferative disease that has spread to other places in the body&#xD;
      (advanced). Drugs used in chemotherapy, such as salsalate, venetoclax, decitabine, and&#xD;
      azacitidine work in different ways to stop the growth of cancer cells, either by killing the&#xD;
      cells, by stopping them from dividing, or by stopping them from spreading.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVE:&#xD;
&#xD;
      I. Determine the tolerability of the addition of standard dose salsalate to the standard&#xD;
      treatment combination of venetoclax + hypomethylating agent (HMA) (decitabine or azacitidine&#xD;
      [5-azacytidine]).&#xD;
&#xD;
      SECONDARY OBJECTIVES:&#xD;
&#xD;
      I. Determine the remission rate and, when feasible, perform exploratory studies of:&#xD;
&#xD;
      Ia. Patterns of mutation clearance. Ib. Distribution of cells with low and high reactive&#xD;
      oxygen species (ROS) content at various points during therapy.&#xD;
&#xD;
      OUTLINE:&#xD;
&#xD;
      CYCLE 1: Patients receive salsalate orally (PO) twice daily (BID) until completion of cycle&#xD;
      1. 24-48 hours later or concurrent with salsalate, patients begin to receive decitabine&#xD;
      intravenously (IV) for 10 days or azacitidine IV for 7 days. Starting 24 hour after&#xD;
      salsalate, patients also receive venetoclax PO continuously until completion of cycle 1.&#xD;
&#xD;
      CYCLE 2: Patients receive decitabine IV for 5 days or azacitidine IV for 7 days, salsalate PO&#xD;
      BID, and venetoclax PO continuously.&#xD;
&#xD;
      Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 26, 2020</start_date>
  <completion_date type="Anticipated">May 22, 2022</completion_date>
  <primary_completion_date type="Anticipated">May 22, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of adverse events of salicylate + venetoclax + decitabine</measure>
    <time_frame>During the first 2 cycles (56 days), up to 3 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Response rates</measure>
    <time_frame>During the first 2 cycles (56 days), up to 3 years</time_frame>
    <description>Wwill correspond response rates with the pattern of survival of low oxygen reactive species cells. The administration of drugs will be timed to determine if there is a measurable added effect of salicylate on the oxidative state of cells when used in combination with venetoclax + decitabine. Next generation sequencing will determine also if there is a correspondence of remission with patterns of mutation clearance and/or effects of treatment on the oxidative state of the leukemia cells.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Acute Myeloid Leukemia</condition>
  <condition>Chronic Myelomonocytic Leukemia</condition>
  <condition>Myeloblasts 10 Percent or More of Bone Marrow Nucleated Cells</condition>
  <condition>Myelodysplastic Syndrome</condition>
  <condition>Myeloproliferative Neoplasm</condition>
  <condition>Recurrent Acute Myeloid Leukemia</condition>
  <condition>Refractory Acute Myeloid Leukemia</condition>
  <condition>Secondary Acute Myeloid Leukemia</condition>
  <arm_group>
    <arm_group_label>Treatment (salsalate, decitabine, azacitidine, venetoclax)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CYCLE 1: Patients receive salsalate PO BID until completion of cycle 1. 24-48 hours later or concurrent with salsalate, patients begin to receive decitabine IV for 10 days or azacitidine IV for 7 days. Starting 24 hour after salsalate, patients also receive venetoclax PO continuously until completion of cycle 1.&#xD;
CYCLE 2: Patients receive decitabine IV for 5 days or azacitidine IV for 7 days, salsalate PO BID, and venetoclax PO continuously.&#xD;
Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Azacitidine</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (salsalate, decitabine, azacitidine, venetoclax)</arm_group_label>
    <other_name>5 AZC</other_name>
    <other_name>5-AC</other_name>
    <other_name>5-Azacytidine</other_name>
    <other_name>5-AZC</other_name>
    <other_name>Azacytidine</other_name>
    <other_name>Azacytidine, 5-</other_name>
    <other_name>Ladakamycin</other_name>
    <other_name>Mylosar</other_name>
    <other_name>U-18496</other_name>
    <other_name>Vidaza</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Decitabine</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (salsalate, decitabine, azacitidine, venetoclax)</arm_group_label>
    <other_name>5-Aza-2''-deoxycytidine</other_name>
    <other_name>Dacogen</other_name>
    <other_name>Decitabine for Injection</other_name>
    <other_name>Deoxyazacytidine</other_name>
    <other_name>Dezocitidine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Salsalate</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Treatment (salsalate, decitabine, azacitidine, venetoclax)</arm_group_label>
    <other_name>Disalcid</other_name>
    <other_name>Mono-Gesic</other_name>
    <other_name>o-Salicylsalicylic Acid</other_name>
    <other_name>Salflex</other_name>
    <other_name>Salicylsalicylic Acid</other_name>
    <other_name>Salsitab</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Venetoclax</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Treatment (salsalate, decitabine, azacitidine, venetoclax)</arm_group_label>
    <other_name>ABT-0199</other_name>
    <other_name>ABT-199</other_name>
    <other_name>ABT199</other_name>
    <other_name>GDC-0199</other_name>
    <other_name>RG7601</other_name>
    <other_name>Venclexta</other_name>
    <other_name>Venclyxto</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically proven acute myelogenous leukemia (AML) or advanced myeloid malignancy&#xD;
             [myelodysplasia; chronic myelomonocytic leukemia (CMML); or chronic myeloproliferative&#xD;
             disease (MPD) each with &gt;= 10% myeloblasts in blood or bone marrow]&#xD;
&#xD;
          -  For patients with de novo AML: must not be a candidate for standard induction therapy&#xD;
             based upon age, co-morbidities, patient choice, high risk features known to have poor&#xD;
             outcomes with standard induction therapy (ELN high risk disease by cytogenetics,&#xD;
             deoxyribonucleic acid [DNA] mutation profile or TP53 mutation)&#xD;
&#xD;
          -  Patients with advanced myelodysplastic syndrome (MDS), secondary AML,&#xD;
             relapsed/refractory AML, prior hypomethylating agent are eligible&#xD;
&#xD;
          -  Patients must give informed consent&#xD;
&#xD;
          -  Patients must have an Eastern Cooperative Oncology Group (ECOG) performance status =&lt;&#xD;
             2&#xD;
&#xD;
          -  Total bilirubin &lt; 2 x upper limit of normal (ULN)&#xD;
&#xD;
          -  Aspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase&#xD;
             [SGOT])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT])&#xD;
             &lt; 2.5 X institutional ULN&#xD;
&#xD;
          -  Creatinine &lt; 2 mg/dL&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  White blood cell (WBC) uncontrolled (&gt; 15,000/uL) despite hydroxyurea or cytarabine x&#xD;
             3 days. Known central nervous system (CNS) AML&#xD;
&#xD;
          -  Serious concomitant systemic disorders (including active infections) that would&#xD;
             compromise the safety of the patient or compromise the patient?s ability to complete&#xD;
             the study, at the discretion of the investigator. Pregnant patients are excluded&#xD;
&#xD;
          -  History of allergic reactions attributed to compounds of similar chemical or biologic&#xD;
             composition to Salsalate or other agents used in the study. Examples include aspirin&#xD;
&#xD;
          -  The effects of venetoclax and decitabine or 5-azacytidine on the developing human&#xD;
             fetus at the recommended therapeutic dose are unknown. For this reason and because&#xD;
             therapeutic agents used in this trial are known to be teratogenic, women of&#xD;
             child-bearing potential and men must agree to use adequate contraception (hormonal or&#xD;
             barrier method of birth control; abstinence) prior to study entry, for the duration of&#xD;
             study participation and for 24 weeks after. Should a woman become pregnant or suspect&#xD;
             she is pregnant while participating in this study, she should inform her treating&#xD;
             physician immediately&#xD;
&#xD;
          -  Patients with immune deficiency are at increased risk of lethal infections when&#xD;
             treated with marrow-suppressive therapy, therefore, known human immunodeficiency virus&#xD;
             (HIV)-positive patients receiving combination anti-retroviral therapy are excluded&#xD;
             from the study because of possible pharmacokinetic interactions with treatment&#xD;
             medications or other agents administered during the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Roger K Strair</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rutgers Cancer Institute of New Jersey</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Rutgers Cancer Institute of New Jersey</name>
      <address>
        <city>New Brunswick</city>
        <state>New Jersey</state>
        <zip>08903</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Roger K. Strair</last_name>
      <phone>732-235-4523</phone>
      <email>strairrk@rutgers.edu</email>
    </contact>
    <investigator>
      <last_name>Roger K. Strair, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>October 29, 2019</study_first_submitted>
  <study_first_submitted_qc>October 29, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 31, 2019</study_first_posted>
  <last_update_submitted>August 20, 2021</last_update_submitted>
  <last_update_submitted_qc>August 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Rutgers, The State University of New Jersey</investigator_affiliation>
    <investigator_full_name>Roger Strair, MD, PhD</investigator_full_name>
    <investigator_title>Professor of Medicine, Chief of Hematologic Malignancies Medical Oncology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Leukemia, Myelomonocytic, Chronic</mesh_term>
    <mesh_term>Leukemia, Myelomonocytic, Juvenile</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Myeloproliferative Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Salicylsalicylic acid</mesh_term>
    <mesh_term>Sodium Salicylate</mesh_term>
    <mesh_term>Azacitidine</mesh_term>
    <mesh_term>Decitabine</mesh_term>
    <mesh_term>Venetoclax</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

